- Home
- PRQR
as 03-13-2025 2:42pm EST
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
| Founded: | 2012 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 309.5M | IPO Year: | 2014 |
| Target Price: | $8.17 | AVG Volume (30 days): | 372.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.61 - $4.62 | Next Earning Date: | 05-08-2025 |
| Revenue: | $20,506,357 | Revenue Growth: | 306.68% |
| Revenue Growth (this year): | 210.18% | Revenue Growth (next year): | 33.25% |
Latest ProQR Therapeutics N.V. News
PRQR Breaking Stock News: Dive into PRQR Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 hours ago
ProQR Announces Year End 2024 Operating and Financial Results
MT Newswires
3 days ago
Citigroup Upgrades ProQR Therapeutics to Buy From Neutral, Price Target is $4
Simply Wall St.
a month ago
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) largest shareholders are individual investors with 60% ownership, institutions own 17%
Simply Wall St.
3 months ago
Is There An Opportunity With ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 37% Undervaluation?
TipRanks
3 months ago
ProQR Therapeutics announces $8.1M in new funding from RSRT
GlobeNewswire
3 months ago
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
GlobeNewswire
3 months ago
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
TipRanks
3 months ago
ProQR Therapeutics price target raised to $8 from $5 at JMP Securities
Compare PRQR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRQR ProQR Therapeutics N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.